Bristol-Myers Squibb Company
BMY NYSEHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Jul 30, 2026
ET
EPS Est.
1.60
EPS Actual
2.04
Revenue Est.
$11.74B
Revenue Actual
$12.97B
Next Earnings Report
Date
Oct 29, 2026 · Thu
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
1.68
Revenue Est.
$12.59B
Company Overview
Bristol-Myers Squibb Company (ticker BMY) is listed on NYSE with a market cap of about $136.88B. Its next earnings report (FY2026 Q3) is expected on Oct 29, 2026 (ET), Pre-market, with consensus EPS of 1.68. In the last 15 reported quarters, EPS beat consensus estimates 14 times.
Actual EPS TrendRecently15Term · Feb 2, 2023 → Jul 30, 2026
Feb 2, 2023Range: -4.40 ~ 2.07Jul 30, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 30, 2026 | -- | 1.60 | Above forecast↑2.04 | $11.74B | $12.97B |
| Apr 30, 2026 | -- | 1.42 | 1.58 | $10.93B | $11.49B |
| Feb 5, 2026 | -- | 1.23 | 1.26 | $12.28B | $12.5B |
| Oct 30, 2025 | -- | 1.52 | 1.63 | $11.85B | $12.22B |
| Jul 31, 2025 | -- | 1.09 | Above forecast↑1.46 | $11.44B | $12.27B |
| Apr 24, 2025 | -- | 1.49 | Above forecast↑1.80 | $10.7B | $11.2B |
| Feb 6, 2025 | -- | 1.47 | 1.67 | $11.57B | $12.34B |
| Oct 31, 2024 | -- | 1.49 | Above forecast↑1.80 | $11.26B | $11.89B |
| Jul 26, 2024 | -- | 1.62 | Above forecast↑2.07 | $11.54B | $12.2B |
| Apr 25, 2024 | -- | -4.41 | -4.40 | $11.48B | $11.87B |
| Feb 2, 2024 | -- | 1.52 | 1.70 | $11.19B | $11.48B |
| Oct 26, 2023 | -- | 1.76 | 2.00 | $10.97B | $10.97B |
| Jul 27, 2023 | -- | 1.99 | 1.75 | $11.8B | $11.23B |
| Apr 27, 2023 | -- | 1.98 | 2.05 | $11.49B | $11.34B |
| Feb 2, 2023 | -- | 1.71 | 1.82 | $11.19B | $11.41B |
Original Filings (SEC)
10-Q2026-07-30 ↗
8-K2026-07-30 ↗
8-K2026-05-08 ↗
10-Q2026-04-30 ↗
8-K2026-04-30 ↗
10-K2026-02-11 ↗
8-K2026-02-05 ↗
8-K2026-01-12 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
